Quantamental Technologies LLC grew its stake in shares of Masimo Co. (NASDAQ:MASI) by 813.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,681 shares of the medical equipment provider’s stock after buying an additional 3,278 shares during the quarter. Quantamental Technologies LLC’s holdings in Masimo were worth $509,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Masimo by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,147,708 shares of the medical equipment provider’s stock valued at $516,556,000 after acquiring an additional 109,065 shares during the period. Vanguard Group Inc raised its holdings in shares of Masimo by 2.7% during the 3rd quarter. Vanguard Group Inc now owns 4,147,708 shares of the medical equipment provider’s stock worth $516,556,000 after acquiring an additional 109,065 shares during the period. FMR LLC raised its holdings in Masimo by 17.8% in the 4th quarter. FMR LLC now owns 3,889,562 shares of the medical equipment provider’s stock valued at $417,622,000 after buying an additional 587,587 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd raised its holdings in Masimo by 12.6% in the 4th quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 779,500 shares of the medical equipment provider’s stock valued at $83,694,000 after buying an additional 87,476 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in Masimo by 13.3% in the 4th quarter. Victory Capital Management Inc. now owns 726,329 shares of the medical equipment provider’s stock valued at $77,986,000 after buying an additional 85,255 shares during the period. 81.79% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have weighed in on the company. UBS Group lifted their target price on Masimo from $147.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Piper Jaffray Companies boosted their price objective on Masimo from $148.00 to $160.00 in a research note on Friday, May 17th. Stifel Nicolaus upped their price target on Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, May 17th. Needham & Company LLC restated a “buy” rating and set a $158.00 price target (up previously from $155.00) on shares of Masimo in a research note on Tuesday, May 7th. Finally, Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $153.00 price objective on the stock in a report on Wednesday, May 8th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Masimo presently has an average rating of “Buy” and an average target price of $154.25.
Shares of MASI traded up $1.65 during midday trading on Wednesday, reaching $140.58. The stock had a trading volume of 373,500 shares, compared to its average volume of 451,693. Masimo Co. has a 52 week low of $96.14 and a 52 week high of $147.91. The company has a market capitalization of $7.45 billion, a PE ratio of 46.40, a P/E/G ratio of 2.81 and a beta of 1.12.
Masimo (NASDAQ:MASI) last issued its earnings results on Monday, May 6th. The medical equipment provider reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.04. Masimo had a return on equity of 18.61% and a net margin of 22.49%. The firm had revenue of $231.70 million for the quarter, compared to the consensus estimate of $223.67 million. During the same quarter in the previous year, the company posted $0.75 earnings per share. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. Research analysts expect that Masimo Co. will post 3.12 earnings per share for the current fiscal year.
In other news, CAO Ramshorst David J. Van sold 1,845 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $140.00, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 1,695 shares in the company, valued at approximately $237,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven Barker sold 10,000 shares of the firm’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the director now owns 74,832 shares of the company’s stock, valued at approximately $10,102,320. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,572 shares of company stock worth $6,300,560. Corporate insiders own 11.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://sundanceherald.com/2019/05/22/quantamental-technologies-llc-boosts-stake-in-masimo-co-masi.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.